BridgeBio Pharma stock

BBIO · NASDAQ · USD

$78.30Change from previous close: +0.17%Absolute change: +$0.13

Close · November 13, 2026

Price history

+20.35% over the period

1 year: from $65.06 (November 13, 2025) to $78.30 (November 13, 2026), +20.35%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$78.30
October 30, 2026$74.95
September 30, 2026$65.80
August 31, 2026$76.59
July 31, 2026$80.09
June 30, 2026$74.48
May 29, 2026$66.26
April 30, 2026$71.11
March 31, 2026$74.26
February 27, 2026$66.48
January 30, 2026$77.27
December 31, 2025$76.49
November 28, 2025$72.01
November 13, 2025$65.06

At a glance

  • The company

    Biopharmaceutical company discovering and developing medicines for genetic diseases including ATTR cardiomyopathy, molybdenum cofactor deficiency, achondroplasia, and other rare conditions

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.42 (estimate -$0.56)

TickerLandia's take on BridgeBio Pharma

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$62.50
52-wk high$93.42

−16.18% from the 52-week high

Analysts · 22 analysts

Average target$106.85+36.46% vs. price

Buy 19 · Hold 3 · Sell 0 · Strong buy

TickerLandia Fingerprint: BridgeBio Pharma

Compared with similar companies: very low earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

How BridgeBio Pharma is valued

Compared with 11 similar companies

BridgeBio Pharma's metrics compared with similar companies
MetricBridgeBio PharmaPosition in the groupBand
Operating margin-37.3%Low
ROE32.8%Middle
Debt/equity-1.35Low
Net margin-59.8%Low
Price/sales16.1High

Grey band: the middle half of the group; tick: the median; dot: BridgeBio Pharma. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$243.68M

Latest quarter · Q2 2026

Net income

-$152.22M

Latest quarter · Q2 2026

Quarterly net margin

-62.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$15.25B
EPS
-$3.03
Volume
1.15M
Daily trading
€200.16M
Dividend yield
0.00%

How BridgeBio Pharma is changing

All results
  • Revenue grew 127.4% a year on average over the last 5 years

  • Operating margin rose from −603.3% to −100.0%

  • Shares outstanding up 62.3% in 5 years

Returns

BridgeBio Pharma returns

$1,000 invested in BridgeBio Pharma 5 years ago, on November 15, 2021, would be worth $1,626 today: +62.58% in total, +10.22% per year. This is the price return only: dividends are excluded.

PeriodBridgeBio PharmaS&P 500$1,000 becomes
1 month+23.70%−3.12%$1,237
6 months+14.12%+1.58%$1,141
Year to date+2.37%+10.46%$1,024
1 year+20.35%+12.23%$1,204
3 years+184.52%+71.41%$2,845
5 years+62.58%+61.48%$1,626

Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

BridgeBio Pharma: technical analysis

BridgeBio Pharma shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 13.2% below its all-time closing high ($90.17, July 9, 2026).

Trend
No clear trend
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+7.71%

Support and resistance

Price areas where BridgeBio Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$85.42+9.09%4 touches, last on August 19, 2026
  2. Resistance$79.06+0.97%8 touches, last on August 17, 2026
  3. Last price$78.30
  4. Support$70.21−10.33%5 touches, last on September 23, 2026
  5. Support$68.13−12.99%2 touches, last on October 2, 2026
  6. Support$64.98−17.02%2 touches, last on September 28, 2026

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
0.95
Volatility (60 sessions, annualised)
35.7%
Largest fall in the last year
−29.80%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

BridgeBio Pharma: seasonality

Average monthly price change over 8 years

−4.3%Jan+1.0%Feb+7.8%Mar−6.8%Apr−3.8%May+14.5%Jun+12.6%Jul+2.9%Aug−6.2%Sep+5.4%Oct+10.3%Nov+4.7%Dec

Over the last 8 years, the strongest month for BridgeBio Pharma has been June: +14.48% on average, positive in 6 years out of 7. The weakest has been April: −6.82% on average, positive in 2 years out of 7. November, the current month, has been positive in 5 years out of 7 (+10.28% on average).

Show chart data
MonthAverageMedianPositive years
January−4.31%−1.60%3 of 7
February+0.96%−0.41%3 of 7
March+7.82%−0.95%3 of 7
April−6.82%−9.22%2 of 7
May−3.80%−5.51%2 of 7
June+14.48%+12.41%6 of 7
July+12.65%+4.99%5 of 8
August+2.86%+4.98%5 of 8
September−6.23%−7.52%2 of 8
October+5.39%+5.12%6 of 8
November+10.28%+14.96%5 of 7
December+4.72%+6.22%5 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

BridgeBio Pharma and its competitors

With 1,081 employees and revenue of 502.1 million USD in the fiscal year ended December 2025, BridgeBio Pharma discovers, develops and delivers medicines for patients with genetic diseases. Its offerings include Attruby, an oral treatment for cardiomyopathy linked to wild-type or transthyretin-mediated amyloidosis, and NULIBRY, an intravenous form of fosdenopterin for molybdenum cofactor deficiency. Late-stage candidates target achondroplasia and hypochondroplasia with low-dose infigratinib, hypocalcemia and hypoparathyroidism with encaleret, and LGMD2I with BBP-418, while the gene therapy BBP-812 addresses Canavan disease.

Headquarters
Palo Alto, United States
Employees
1,081
Founded
2015
Chief executive
Neil Kumar
BridgeBio Pharma and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BridgeBio PharmaBBIO$15.25B-37.3%—+14.12%
Jazz PharmaceuticalsJAZZ$15.5B27.4%71.5+3.97%
ExelixisEXEL$16.84B40.2%20.7+34.53%
Ascendis PharmaASND$18.06B30.9%18.1+13.06%
Bio-TechneTECH$11.44B21.7%66.8+62.17%
Halozyme TherapeuticsHALO$11.43B56.7%25.1+43.18%

Same industry or related industries, similar size. Compare BridgeBio Pharma with its competitors · Full profile